Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seventeen analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $35.0833.
Several brokerages have recently commented on DNLI. Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. Robert W. Baird raised their price objective on Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Wall Street Zen raised shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday. Finally, BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Denali Therapeutics in a report on Monday, May 11th.
Get Our Latest Analysis on DNLI
Institutional Investors Weigh In On Denali Therapeutics
Denali Therapeutics Trading Down 1.7%
NASDAQ DNLI opened at $22.90 on Tuesday. The company has a market capitalization of $3.63 billion, a price-to-earnings ratio of -7.95 and a beta of 0.96. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. Denali Therapeutics has a 12 month low of $12.58 and a 12 month high of $27.30. The company’s fifty day moving average price is $22.27 and its two-hundred day moving average price is $20.66.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same quarter in the prior year, the company posted ($0.78) earnings per share. As a group, research analysts predict that Denali Therapeutics will post -2.74 earnings per share for the current fiscal year.
Denali Therapeutics Company Profile
Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.
Featured Articles
- Five stocks we like better than Denali Therapeutics
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
